tiprankstipranks
Trending News
More News >

Akeso’s Ivonescimab Shows Promise in NSCLC Treatment

Akeso’s Ivonescimab Shows Promise in NSCLC Treatment

Akeso, Inc. (HK:9926) has released an update.

Confident Investing Starts Here:

Akeso, Inc. has announced significant progress in the treatment of PD-L1 positive advanced NSCLC with its drug ivonescimab, showing a marked improvement over pembrolizumab in a recent Phase III clinical trial. The drug not only achieved a median progression-free survival (PFS) of 11.14 months versus 5.82 for the control but also demonstrated a better overall response rate and disease control rate. These promising results have led to the acceptance of a supplemental New Drug Application by China’s NMPA and plans for further international Phase III trials.

For further insights into HK:9926 stock, check out TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App